ArticleFrontiers in bioengineering and biotechnology2026
From mRNA stabilisation to mirror life: Biological orthogonality, incremental risk, and anticipatory governance.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Molecular stabilisation of mRNA is central to the development of therapeutics. Stabilisation is gained through modifications that cause mRNA to resist degradation, evade immune recognition, and prolong expression. These modifications introduce degrees of biological orthogonality, which, in this context, is the extent to which a molecule becomes invisible to the natural systems that would otherwise process or eliminate it. We propose that orthogonality provides a framework for understanding biosecurity risks across the spectrum of synthetic nucleic acid modification, from current mRNA therapeutics to mirror life. We develop this framework through a five-stage continuum from engineered mRNA to fully orthogonal mirror-life systems, using the 2024 scientific moratorium that was recommended for mirror life as a biosecurity governance endpoint. Across this spectrum, there is an increasing degree to which engineered genetic material can resist degradation and evade immune recognition, and a threshold at which this genetic material could be replicated. mRNA has minimal biosecurity issues because it is detectable, immunologically decomposable and unable to replicate, whereas mirror life would be highly undetectable, minimally decomposable, and replicable. Orthogonality, however, does not appear only at these extremes, and we suggest that biosecurity-relevant risks can accumulate progressively as we engineer greater orthogonality. Orthogonality should be a significant factor in designing biosecurity governance, alongside sequence screening and product-level assessments. We suggest a trajectory-focused oversight that monitors, across research programmes, the properties that turn orthogonality into risk and triggers staged reviews as they advance. The properties in question are persistence, reflected in half-life extension, nuclease resistance, and environmental persistence, along with invisibility to recognition and surveillance and the capacity for autonomous replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.